SGMT

Sagimet Biosciences Inc.

Healthcare
Biotechnology
$355M market cap

Forecast run · Sep 14, 2026Upside rank 490 of 3,136

Model Signal

ForecastQ Daily Probabilities

55.9%

66.3%

36.5%

Analyst Consensus

Recommendation2.13/5 Buy

Last price$10.88

Price target$18.00

Implied move+65.4%

Analysts8

ForecastQ Portfolios

SGMT is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.